# Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

> **NCT06217302** · PHASE3 · RECRUITING · sponsor: **Alessandro Doria** · enrollment: 150 (estimated)

## Conditions studied

- Diabetic Nephropathies
- Kidney Failure, Chronic
- Diabetes Mellitus Type 1
- Heart Failure

## Interventions

- **DRUG:** Sotagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06217302
- **Lead sponsor:** Alessandro Doria
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-31
- **Primary completion:** 2028-12
- **Final completion:** 2029-05
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06217302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06217302, "Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06217302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*